Vinten-Johansen Jakob, Zhao Zhi-Qing, Jiang Rong, Zatta Amanda J
Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center, Emory Crawford Long Hospital, Atlanta, GA 30308-2225, USA.
Expert Rev Cardiovasc Ther. 2005 Nov;3(6):1035-45. doi: 10.1586/14779072.3.6.1035.
Reperfusion is the definitive treatment for coronary occlusive disease. However, reperfusion carries the potential to exacerbate lethal injury, termed 'reperfusion injury'. Studies have suggested that reperfusion injury events are triggered during the early moments of reflow, and determine, in part, the severity of downstream manifestations of postischemic injury, including endothelial dysfunction, infarction and apoptosis. The application of brief iterative episodes of reflow (reoxygenation) and reocclusion (ischemia, hypoxia) at the immediate onset of reperfusion, which has been termed 'postconditioning' by the authors, reduces many manifestations of postischemic injury, notably infarct size, apoptosis, coronary vascular endothelial injury and reperfusion arrhythmias. Cardioprotection with postconditioning has been reported to be comparable with that observed using the gold standard maneuver ischemic preconditioning. In contrast to preconditioning, which exerts its effects primarily during the index ischemia, postconditioning appears to exert its effects during reperfusion alone. Postconditioning modifies the early phase of reperfusion in ways that are just beginning to be understood. It appears to first: reduce the oxidant burden and consequent oxidant-induced injury; secondly, attenuate the local inflammatory response to reperfusion; and thirdly, engage end effectors and signaling pathways implicated in other cardioprotective maneuvers, such as ischemic and pharmacologic preconditioning. Postconditioning seems to trigger the upregulation of survival kinases principally known to attenuate the pathogenesis of apoptosis and possibly necrosis. The postconditioning phenomenon has been reproduced by a number of independent laboratories and has been observed in both large and small animal in vivo models, as well as in ex vivo and cell culture models. In contrast to preconditioning, postconditioning may have widespread clinical application because it can be applied during reperfusion at the point of service for angioplasty, stenting, cardiac surgery and organ transplantation.
再灌注是治疗冠状动脉闭塞性疾病的决定性方法。然而,再灌注有可能加剧致命性损伤,即“再灌注损伤”。研究表明,再灌注损伤事件在再灌注的早期阶段触发,并在一定程度上决定了缺血后损伤下游表现的严重程度,包括内皮功能障碍、梗死和细胞凋亡。在再灌注开始时立即应用短暂的反复再灌注(复氧)和再闭塞(缺血、缺氧),作者将其称为“后适应”,可减少缺血后损伤的许多表现,尤其是梗死面积、细胞凋亡、冠状动脉血管内皮损伤和再灌注心律失常。据报道,后适应的心脏保护作用与使用金标准策略缺血预处理所观察到的作用相当。与主要在指数缺血期间发挥作用的预处理不同,后适应似乎仅在再灌注期间发挥作用。后适应以刚刚开始被理解的方式改变再灌注的早期阶段。它似乎首先:减轻氧化应激负担以及随之而来的氧化应激诱导的损伤;其次,减轻对再灌注的局部炎症反应;第三,激活与其他心脏保护策略(如缺血预处理和药物预处理)相关的终末效应器和信号通路。后适应似乎触发了主要已知可减轻细胞凋亡和可能坏死发病机制的存活激酶的上调。后适应现象已被多个独立实验室重现,并在大型和小型动物体内模型以及离体和细胞培养模型中观察到。与预处理不同,后适应可能具有广泛的临床应用,因为它可以在血管成形术、支架置入术、心脏手术和器官移植的服务点在再灌注期间应用。